K
Kelan (Shanghai) Pharmaceutical Technology
Developing novel drugs targeting metabolic diseases and oncology through advanced R&D pipelines
About Kelan (Shanghai) Pharmaceutical Technology
Cholesgen operates in the pharmaceutical sector, focusing on the research and development of novel drugs targeting metabolic diseases and oncology. The company leverages a unique R&D perspective, integrating principles of biochemistry, disease biology, medicinal chemistry, and translational medicine. Its founding team comprises R&D experts from leading domestic and international pharmaceutical companies, alongside researchers from top Chinese institutes. Cholesgen's advisory team includes senior scientists and professors specializing in metabolism, life sciences, and medicinal chemistry. The company recently secured over 100 million RMB in Series A financing, which will be used to accelerate the development of its core drug pipeline, expand its R&D team, and enhance external collaborations. Cholesgen's business model revolves around building differentiated R&D pipelines based on new mechanisms in metabolic and oncology research, aiming to develop drugs for new targets. The company serves clients in the healthcare and pharmaceutical markets, generating revenue through the development and potential commercialization of its drug candidates.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Cardiology and cardiovascular, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2025 | $14M | $55M | SDIC Venture Capital | ↗ |
| SERIES A✓Equity / VC | Jun 2023 | $14M | $55M | Gaorong Ventures · CICC · Dawu Venture Capital · Trinity Innovation Fund | ↗ |
Growth signals
Latest recorded traffic for Kelan (Shanghai) Pharmaceutical Technology is 60 monthly website visits, up 0% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kelan (Shanghai) Pharmaceutical Technology in its local ecosystem
The Kelan (Shanghai) Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Gaorong Ventures
CICC- DCDawu Venture Capital
Trinity Innovation Fund- NFNanwan Baiao Fund
SDIC Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kelan (Shanghai) Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kelan (Shanghai) Pharmaceutical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









